References of "WANG, A"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailThe risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies
Kendler, D.L.; Chines, A.; Brandi, M.L. et al

in Osteoporosis International (2019), 30(1), 71-78

Summary: This post-hoc analysis queried whether women experiencing fracture on denosumab indicates inadequate treatment response or whether the risk of subsequent fracture remains low with continuing ... [more ▼]

Summary: This post-hoc analysis queried whether women experiencing fracture on denosumab indicates inadequate treatment response or whether the risk of subsequent fracture remains low with continuing denosumab. Results showed that denosumab decreases the risk of subsequent fracture and fracture sustained while on denosumab is not necessarily indicative of inadequate treatment response. Introduction: This analysis assessed whether a fracture sustained during denosumab therapy indicates inadequate treatment response and if the risk of a subsequent fracture decreases with continuing denosumab treatment. Methods: In FREEDOM, a clinical trial to evaluate the efficacy and safety of denosumab, postmenopausal women with osteoporosis were randomized to placebo or denosumab for 3 years. In the 7-year FREEDOM Extension, all participants were allocated to receive denosumab. Here we compare subsequent osteoporotic fracture rates between denosumabtreated subjects during FREEDOM or the Extension and placebo-treated subjects in FREEDOM. Results: During FREEDOM, 438 placebo- and 272 denosumab-treated subjects had an osteoporotic fracture. Exposure-adjusted subject incidence per 100 subject-years was lower for denosumab (6.7) vs placebo (10.1). Combining all subjects on denosumab from FREEDOM and the Extension for up to 10 years (combined denosumab), 794 (13.7%) had an osteoporotic fracture while on denosumab. Of these, one or more subsequent fractures occurred in 144 (18.1%) subjects, with an exposure-adjusted incidence of 5.8 per 100 subject-years, similar to FREEDOM denosumab (6.7 per 100 subject-years) and lower than FREEDOM placebo (10.1 per 100 subjectyears). Adjusting for prior fracture, the risk of having a subsequent on-study osteoporotic fracture was lower in the combined denosumab group vs placebo (hazard ratio [95% CI]: 0.59 [0.43–0.81]; P = 0.0012). Conclusions: These data demonstrate that denosumab decreases the risk of subsequent fracture and a fracture sustained while on denosumab is not necessarily indicative of inadequate treatment response. [less ▲]

Detailed reference viewed: 25 (4 ULiège)
Full Text
Peer Reviewed
See detailRelationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment
Ferrari, S.; Libanati, C.; Lin, CJF et al

in Journal of Bone and Mineral Research (2019), 34

Although treat-to-target strategies are being discussed in osteoporosis, there is little evidence of what the target should be to maximally reduce fracture risk. We investigated the relationship between ... [more ▼]

Although treat-to-target strategies are being discussed in osteoporosis, there is little evidence of what the target should be to maximally reduce fracture risk. We investigated the relationship between total hip BMD T-score and the incidence of nonvertebral fracture in women who received up to 10 years of continued denosumab therapy in the FREEDOM trial (3 years) and its long-term Extension (up to 7 years). We report the percentages of women who achieved a range of T-scores at the total hip or femoral neck over 10 years of denosumab treatment (1,343 women completed 10 years of treatment). The incidence of nonvertebral fractures was lower with higher total hip T-score. This relationship plateaued at a T-score between –2.0 and –1.5 and was independent of age and prevalent vertebral fractures, similar to observations in treatment-naïve subjects. Reaching a specific T-score during denosumab treatment was dependent on the Baseline T-score, with higher T-scores at baseline more likely to result in higher T-scores at each time point during the study. Our findings highlight the importance of follow-up BMD measurements in patients receiving denosumab therapy, since BMD remains a robust indicator of fracture risk. These data support the notion of a specific T-score threshold as a practical target for therapy in osteoporosis. [less ▲]

Detailed reference viewed: 21 (2 ULiège)
Full Text
Peer Reviewed
See detail10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
Bone, H.G.; Wagman, R.B.; Brandi, M.L. et al

in Lancet Diabetes and Endocrinology (2017), 5

Detailed reference viewed: 139 (4 ULiège)
Full Text
Peer Reviewed
See detailThe risk of subsequent osteoporotic fractures is decreased in patients experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies.
Kendler, D.L.; Chines, A.; Brandi, M.L. et al

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 45 (3 ULiège)
Full Text
Peer Reviewed
See detailThe risk of subsequent osteoporotic fractures is decreased in patients experiencing fracture while on denosumab.
Kendler, D.L.; Chines, A.; Brandi, M.L. et al

in Arthritis and Rheumatism (2016, September), 68S10

Detailed reference viewed: 18 (2 ULiège)
Full Text
Peer Reviewed
See detailTen years of Denosumab (DMAB) treatment in postmenopausal women with osteoporosis. Results from the FREEDOM Extension trial.
Bone, H.G.; Brandi, M.L.; Brown, J.P. et al

in Osteoporosis International (2016, April), 27(Supplement 1), 135-136

Detailed reference viewed: 231 (3 ULiège)
Full Text
Peer Reviewed
See detailrelationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 10 years of Denosumab (DMAB) treatment
Ferrari, S.; ADAMI, S.; Brown, J.P. et al

in Osteoporosis International (2016, April), 27(Supplement 1), 49-50

Detailed reference viewed: 62 (4 ULiège)
Full Text
Peer Reviewed
See detailA randomized double-blind study of Denosumab (DMAB) compared with Zoledronic acid (ZOL) in postmenopausal women with osteoporosis previously treated with oral bisphosphonates
Miller, P.; Pannacciulli, N.; Brown, J.P. et al

in Osteoporosis International (2016, April), 27(SUPPLEMENT1), 42

Detailed reference viewed: 86 (3 ULiège)
Full Text
Peer Reviewed
See detailThe effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
PAPAPOULOS, S.; LIPPUNER, K.; ROUX, C. et al

in Osteoporosis International (2015), 26(12), 2773-2783

Summary: The FREEDOM study and its Extension provide long-term information about the effects of denosumab for the treatment of postmenopausal osteoporosis. Treatment for up to 8 years was associated with ... [more ▼]

Summary: The FREEDOM study and its Extension provide long-term information about the effects of denosumab for the treatment of postmenopausal osteoporosis. Treatment for up to 8 years was associated with persistent reduction of bone turnover, continued increases in bone mineral density, low fracture incidence, and a favorable benefit/risk profile. Introduction: This study aims to report the results through year 5 of the FREEDOM Extension study, representing up to 8 years of continued denosumab treatment in postmenopausal women with osteoporosis. Methods : Women who completed the 3-year FREEDOM study were eligible to enter the 7-year open-label FREEDOM Extension in which all participants are scheduled to receive denosumab, since placebo assignment was discontinued for ethical reasons. A total of 4550 women enrolled in the Extension (2343 long-term; 2207 cross-over). In this analysis, women in the long-term and cross-over groups received denosumab for up to 8 and 5 years, respectively. Results Throughout the Extension, sustained reduction of bone turnover markers (BTMs) was observed in both groups. In the long-term group, mean bone mineral density (BMD) continued to increase significantly at each time point measured, for cumulative 8-year gains of 18.4 and 8.3 % at the lumbar spine and total hip, respectively. In the cross-over group, mean BMD increased significantly from the Extension baseline for 5-year cumulative gains of 13.1 and 6.2 % at the lumbar spine and total hip, respectively. The yearly incidence of new vertebral and nonvertebral fractures remained low in both groups. The incidence of adverse and serious adverse events did not increase over time. Through Extension year 5, eight events of osteonecrosis of the jaw and two events of atypical femoral fracture were confirmed. [less ▲]

Detailed reference viewed: 26 (3 ULiège)
Full Text
Peer Reviewed
See detailPourcentage de femmes atteignant des T-scores de DMO non ostéoporotiques au rachis lombaire (RL) et à la hanche totale (HT) après 8 ans de traitement par denosumab (DMAb)
Ferrari, S.; Libanati, C.; Lin, J. et al

in Revue du Rhumatisme (2015, November), 82(S1), 35-36

Detailed reference viewed: 19 (2 ULiège)
Full Text
Peer Reviewed
See detailCan we use bone turnover markers as targets for antiresorptive treatment in postmenopausal osteoporosis ? an analysis from two phase 3 clinical trials.
BROWN, J.P.; DAKIN, P.; HADJI, P. et al

in Arthritis and Rheumatology (2015), 67(S10), 515-517

Detailed reference viewed: 32 (5 ULiège)
Full Text
Peer Reviewed
See detailRelationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 8 years of denosumab treatment
FERRARI, S.; LIBANATI, C.; LIN, CJF. et al

in Arthritis and Rheumatology (2015), 67(s10), 487-489

Detailed reference viewed: 41 (5 ULiège)
Full Text
Peer Reviewed
See detailFurther reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
FERRARI, S.; ADACHI, J.D.; LUPPUNER, K. et al

in Osteoporosis International (2015), 26

Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmenopausal women receiving denosumab for 7 years, nonvertebral fracture rates significantly decreased in ... [more ▼]

Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmenopausal women receiving denosumab for 7 years, nonvertebral fracture rates significantly decreased in years 4–7 versus years 1–3. This is the first demonstration of a further benefit on fracture outcomes with long-term therapy for osteoporosis. Introduction This study aimed to evaluate whether denosumab treatment continued beyond 3 years is associated with a further reduction in nonvertebral fracture rates. Methods Participants who completed the 3-year placebocontrolled Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months (FREEDOM) study were invited to participate in an open-label extension. The present analysis includes 4,074 postmenopausal women with osteoporosis (n=2,343 long-term; n=1,731 cross-over) who enrolled in the extension, missed ≤1 dose during their first 3 years of denosumab treatment, and continued into the fourth year of treatment. Comparison of nonvertebral fracture rates during years 1–3 of denosumab with that of the fourth year and with the rate during years 4–7 was evaluated. Results For the combined group, the nonvertebral fracture rate per 100 participant-years was 2.15 for the first 3 years of denosumab treatment (referent) and 1.36 in the fourth year (rate ratio [RR]=0.64; 95 % confidence interval (CI)=0.48 to 0.85, p=0.003). Comparable findings were observed in the groups separately and when nonvertebral fracture rates during years 1–3 were compared to years 4–7 in the longterm group (RR=0.79; 95 % CI=0.62 to 1.00, p=0.046). Fracture rate reductions in year 4 were most prominent in subjects with persisting low hip bone mineral density (BMD). Conclusions Denosumab treatment beyond 3 years was associated with a further reduction in nonvertebral fracture rate that persisted through 7 years of continuous denosumab administration. The degree to which denosumab further reduces nonvertebral fracture risk appears influenced by the hip bone density achieved with initial therapy [less ▲]

Detailed reference viewed: 29 (6 ULiège)
Full Text
Peer Reviewed
See detailPercentage of women achieving non-osteoporotic BMD T-scores at the lumbar spine (LS) and total hip (TH) during up to 8 years of Denosumab (Dmab) treatment
Ferrari, S; Libanati, C; Lin, CJF et al

in Osteoporosis International (2015), 26(S1), 149-150

Detailed reference viewed: 66 (4 ULiège)
Full Text
Peer Reviewed
See detailDenosumab treatment in postmenopausal women with osteoporosis for up to 9 years: results through year 6 of the freedom extension
Papapoulos, S; Roux, C; Bone, HG et al

in Osteoporosis International (2015), 26(S1), 37-39

Detailed reference viewed: 190 (3 ULiège)
Full Text
Peer Reviewed
See detailPercentage of women achieving non-osteoporotic BMD T-scores at the spine and hip over 8 years of denosumab treatment
Ferrari, S; Libanati, C; Lin, CJF et al

in Arthritis and Rheumatism (2014), 66(11), 986-987

Detailed reference viewed: 58 (4 ULiège)
Full Text
Peer Reviewed
See detailEffect of denosumab treatment in postmenopausal women with osteoporosis: eight-year results from the freedom extension, phase 3 clinical trial
Lewieck, E; Papapoulos, S; Lippuner, K et al

in Endocrine Reviews (2014), 35(3), 22-1

Detailed reference viewed: 21 (1 ULiège)
Full Text
Peer Reviewed
See detailEight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the freedom extension
Papapoulos, S; Lippuner, K; Roux, C et al

in Osteoporosis International (2014), 25(2), 46-47

Detailed reference viewed: 391 (2 ULiège)
Full Text
Peer Reviewed
See detailFurther reduction in nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the freedom extension
Ferrari, S; Adachi, JD; Lippuner, K et al

in Osteoporosis International (2014), 25(2), 56

Detailed reference viewed: 62 (3 ULiège)
Full Text
Peer Reviewed
See detailRelationship between changes in bone mineral density and incidence of fracture with 6 years of Denosumab treatment
Bolognese, MA; Miller, PD; Reginster, Jean-Yves ULiege et al

in Arthritis and Rheumatism (2012), 64(S10), 847

Detailed reference viewed: 28 (1 ULiège)